OBIO — ORCHESTRA BIOMED HOLDINGS INC. (Healthcare >> Biotechnology)
OBIO FAQ
What is OBIO's P/E ratio?
ORCHESTRA BIOMED HOLDINGS INC. (OBIO) currently trades at a P/E ratio of 37.01.
What is OBIO's ROE?
ORCHESTRA BIOMED HOLDINGS INC. reports a Return on Equity (ROE) of -107.20%.
What is OBIO's dividend yield?
ORCHESTRA BIOMED HOLDINGS INC. offers a dividend yield of 0.00%.
What is OBIO's Deepscope Quality Score?
Deepscope rates OBIO's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OBIO?
Deepscope's AI Timing Score for OBIO is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OBIO belong to?
ORCHESTRA BIOMED HOLDINGS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.90
Price
-0.09
(-2.26%)
Day Change
|
|
|---|
OBIO Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 38) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...
| Yếu tố Chất lượng |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.90 |
| PBV / Sector |
4.54 / 4.63
|
| Earning Per Share | -0.92 |
| PE / Sector |
37.01 / 17.43
|
| PEG or PE/Growth / Sector |
15.88 / 0.53
|
| Average 1M Daily Value |
1.01 M
GREAT
|
| Average 1W Daily Value |
0.78 M
GREAT
|
| Yếu tố Kỹ thuật |
|
57% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
64% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-06 09:09:05 |
| Symbol | OBIO |
| Name | ORCHESTRA BIOMED HOLDINGS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 59.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 231.14 / 8,857.28 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 150 Union Square Drive, New Hope, PA, United States, 18938
Phone: 215 862 5797
Website: https://www.orchestrabiomed.com
Employees: 86
Sector: Healthcare >> Biotechnology
Description: Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google